Japan Palmoplantar Pustulosis (PPP) Market is growing with factors such as the increasing number of smoker, increase in cases of metal allergies, increasing women population, presence of diversified treatment and also increase in cases of metal allergies option are some of the driving factors driving the segment growth in the market.
Increasing number of biologic drug approval for PPP and rising disposable income has propelled the demand of the market. However, high cost of treatment and lack of diagnosis have decreased the demand of the market.
Japan Palmoplantar Pustulosis (PPP) Market Scenario
According to Data Bridge Market Research, the market for palmoplantar pustulosis (PPP) in Japan is growing with the market leader such as Novartis AG which accounts an estimated market share of approximately 29.91% The Company has gained outstanding sale through providing palmoplantar pustulosis (PPP) treatment. In January 2019, Novartis AG received positive result from the phase III clinical trial of Cosentyx (an anti-inflammatory drug) in order to treat patients with moderate to severe forms of plaque psoriasis. Palmoplantar pustulosis is one of the symptom which is associated with plaque psoriasis, thus this product is also used for treatment of inflammatory conditions associated with PPP. The result obtained thus allowed the company to expand its root in PPP market.
Trends Impacting the Market
The Japan palmoplantar pustulosis (PPP) market is becoming more competitive with companies such as Novartis AG, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.), AbbVie Inc. as they are the top dominating companies in Japan palmoplantar pustulosis (PPP) market having maximum number of products. Data Bridge Market Research new reports highlight the major growth factors and opportunities in the Japan palmoplantar pustulosis (PPP) market.
For more analysis on the Japan palmoplantar pustulosis (PPP) market request for a briefing with our analysts https://www.databridgemarketresearch.com/fr/speak-to-analyst/?dbmr=japan-palmoplantar-pustulosis-ppp-market
The Japan Palmoplantar Pustulosis (PPP) Market Developments
- In July 2020, Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.) received U.S. FDA approval for STELARA (ustekinumab), a monoclonal antibody indicated for treatment of inflammatory conditions. The approval proved that the drug has the capability to suppress overactive inflammatory response. This approval thus paved the way for the company to sale its product in order to treat palmoplantar pustulosis, which in turn boosted the company’s revenue.
- In January 2018, AbbVie Inc. updated Humira an adalimumab formulation with the addition of citrate buffer. This product update allowed the pediatric patients to consume this product. This product formulation update has allowed the company to enhance the product access to more and more people of different age group and hence boosted the company’s sales and overall revenue.
Scope of the Japan Palmoplantar Pustulosis (PPP) Market
All country based analysis of the Japan palmoplantar pustulosis (PPP) market is further analyzed based on further segmentation. On the basis of disease type, the Japan palmoplantar pustulosis (PPP) market is segmented into type A, and type B. On the basis of severity, the Japan palmoplantar pustulosis (PPP) market is segmented into mild-moderate and moderate-severe. On the basis of type, the Japan palmoplantar pustulosis (PPP) market is segmented into diagnosis, and treatment. On the basis of population type, the Japan palmoplantar pustulosis (PPP) market is segmented into children and adults. On the basis of route of administration, the Japan palmoplantar pustulosis (PPP) market is segmented into oral, topical, parenteral. On the basis of end user, the Japan palmoplantar pustulosis (PPP) market is segmented into hospitals, specialty clinics, diagnostic centers, home healthcare. On the basis of distribution channel, the Japan palmoplantar pustulosis (PPP) Market is segmented into direct tender, hospital pharmacies, retail pharmacies, and online pharmacies.
Key Pointers Covered in the Japan Palmoplantar Pustulosis (PPP) Market Industry Trends and Forecast to 2027
- Market Size
- Top to Bottom Market Analysis
- Recent Developments for Market Competitors
- Recent Market Value for Different Countries
- Market value and over view of palmoplantar pustulosis (PPP) market
- Company profiling of top eight players of palmoplantar pustulosis (PPP) market
Key Market Competitors Covered in the Japan Palmoplantar Pustulosis (PPP) Market Report
The key market players for Japan palmoplantar pustulosis (PPP) market are listed below:
- Novartis AG,
- Eli Lilly and Company
- Boehringer Ingelheim International GmbH
- Amgen Inc.
- Janssen Pharmaceuticals, Inc. (A Subsidiary of Johnson & Johnson Services, Inc.)
- AbbVie Inc.
- Bristol-Myers Squibb Company
- Perrigo Company plc
- ingenus Pharmaceuticals
- F. Hoffmann-La Roche Ltd
- WOCKHARDT
- Bausch Health Companies Inc.
- Mylan N.V.
- ALEOR Dermaceuticals Limited
- Amneal Pharmaceuticals LLC.
- Xiromed
- Encube Ethicals
Above are the key players covered in the report, to know about more and exhaustive list of the Japan palmoplantar pustulosis (PPP) market companies’, contact us: https://www.databridgemarketresearch.com/fr/toc/?dbmr=japan-palmoplantar-pustulosis-ppp-market
Research Methodology: Japan Palmoplantar Pustulosis (PPP) Market
Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Primary Respondents
- Demand Side: Pharmacists, Hospitals, Clinicians and Technicians, Dermatologists, Academic Professionals and Researchers
- Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Related Reports
- Global Psoriasis Treatment Market - Industry Trends and Forecast to 2027
- Global Plaque Psoriasis Market - Industry Trends and Forecast to 2027
- Global Anti-Inflammatory Therapeutics Market - Industry Trends and Forecast to 2027
Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/fr/report-category/healthcare/
